Gainplan’s Viking Therapeutics VKTX Stock Holding History

Gainplan’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-41,500	Closed	-$2.08K	–	62
2024 Q4	$2.08K	Buy	+41,500	New	+$2.37M	﹤0.01%	55

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Gainplan's VKTX Position: Q2 2024 in Review

Gainplan sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 3,005 shares — an estimated $246K sold.

Gainplan first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $246K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Gainplan reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Gainplan sold 3,005 Viking Therapeutics shares in Q2 2024, an estimated $246K.
Gainplan first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
Gainplan's Viking Therapeutics position peaked at $246K in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Gainplan's 13F filing for Q2 2024, filed 12 Jul 2024.